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abstract
PURPOSE Despite extensive randomized evidence supporting the use of treatment breaks in metastatic co-
lorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without
detriment to overall survival (OS). FOCUS4-N was set up to explore the impact of oral maintenance therapy in
patients who are responding to first-line therapy.
METHODS FOCUS4 was a molecularly stratified trial program that registered patients with newly diagnosed
mCRC. The FOCUS4-N trial was offered to patients in whom a targeted subtrial was unavailable or biomarker
tests failed. Patients were randomly assigned using a 1:1 ratio between maintenance capecitabine and active
monitoring (AM). The primary outcome was progression-free survival (PFS) with secondary outcomes including
OS toxicity and tolerability.
RESULTS Between March 2014 and March 2020, 254 patients were randomly assigned (127 to capecitabine
and 127 to AM) across 88 UK sites. Baseline characteristics were balanced. There was strong evidence of
efficacy for PFS (hazard ratio 5 0.40; 95% CI, 0.21 to 0.75; P , .0001), but no significant improvement in OS
(hazard ratio, 0.93; 95% CI, 0.69 to 1.27; P 5 .66) was observed. Compliance with treatment was good, and
toxicity from capecitabine versus AM was as expected with grade $ 2 fatigue (25% v 12%), diarrhea (23% v
13%), and hand-foot syndrome (26% v 3%). Quality of life showed little difference between the groups.
CONCLUSION Despite strong evidence of disease control with maintenance therapy, OS remains unaffected and
FOCUS4-N provides additional evidence to support the use of treatment breaks as safe management alter-
natives for patients who are stable or responding to first-line treatment for mCRC. Capecitabine without
bevacizumab may be used to extend PFS in the interval after 16 weeks of first-line therapy.
J Clin Oncol 39:3693-3704. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Treatment breaks in patients receiving palliative
chemotherapy for metastatic colorectal cancer
(mCRC) reduce toxicity burden and improve quality of
life (QoL).1 However, current standards either mandate
or recommend a strategy of continuing therapy, until
progression or excess toxicity. Standard maintenance
strategies in high-income countries favor combined
oral capecitabine with intravenous bevacizumab once
every 3 weeks,2,3 on the basis of the phase III CAIRO34
and AIO-02075 studies. Health economic evaluation of
this approach has previously indicated a lack of cost-
effectiveness driven by nonsignificant improvement in
overall survival (OS) and high costs of intravenous
bevacizumab (drug plus administration).6 Previous
studies have evaluated a range of strategies to either
completely stop therapy as a treatment holiday, re-
ducing toxicities and hospital visits, or attenuate
therapy, removing certain drugs as a maintenance
therapy in comparison with historic standard-of-care
continuation of maximum tolerated dose of treatment.
Meta-analysis of these approaches overall shows no
difference in OS.7 Notably, maintenance strategies,
almost uniformly, demonstrate an improvement in
progression-free survival (PFS), but at the expense of
ongoing (though attenuated) toxicity and unending
multiple hospital visits for intravenous therapy. In the
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program, see the Data Supplement [online only]), we have
explored the oral strategy of capecitabine only versus active
monitoring (AM). This will allow us to study the potential
impact on PFS, toxicity, and QoL, which will enable patients
and clinicians to choose an optimum approach tailored to
the individual.
The FOCUS4 trial program is a molecularly stratified um-
brella platform trial (Data Supplement) that evaluated safety
and efficacy of novel treatments in targeted biomarker
subgroups within a phase II or III trial setting. The trial used
adaptive statistical methodology that allowed the addition of
new therapies and the dropping of ineffective ones and
including a nonstratified comparison (FOCUS4-N) for pa-
tients in whom a molecularly stratified comparison was
unavailable or the biomarker tests failed for their tumor
tissue. In the Data Supplement, we describe the design and
methods for patient registration and biomarker testing. In
this article, we report the findings of FOCUS4-N, which
tested the efficacy of capecitabine as a maintenance
therapy versus AM in patients with mCRC.
METHODS
Trial Approvals, Patient Eligibility, and Recruitment
The trial and subsequent amendments were approved by
the UKNational Ethics Committee Oxford (reference 13/SC/
0111) and by the relevant regulatory body MHRA (CTA#
20363/0400/001 and EudraCT# 2012-005111-12).
Patients age at least 18 years with newly diagnosed locally
advanced or mCRC were eligible for registration in the
FOCUS4 trial program (see the Data Supplement for details
of FOCUS4 design and registration methods). Patients
whose tumors had remained stable or responded to
treatment according to their 16-week computed tomog-
raphy (CT) were assessed for eligibility for the FOCUS4-N
comparison. In addition to the registration eligibility criteria,
patients were required to have a baseline randomly
assigned CT scan performed within 4 weeks prerandom-
ization; a minimum 3-week washout period between the
last chemotherapy or biologic therapy dose and the first
capecitabine dose; adequate renal (creatinine clear-
ance . 50 mL/min) and liver function; and a WHO per-
formance status of 0-2. Patients who were eligible for either
FOCUS4-N or a molecularly stratified trial were offered
entry into either and given the option of which study to
participate in, followed by appropriate consent.
In the first phase of FOCUS4 between January 2014 and
June 2017, patients with raised baseline platelet count
(thrombocytosis) were considered ineligible on the basis of
previous data from the COIN trial (which indicated a sig-
nificant survival detriment in this patient group receiving an
intermittent strategy).1 A subsequent individual patient data
meta-analysis of phase II or III intermittent strategy trials did
not confirm the observation from COIN.8 Thus, between
June 2017 and March 2020, eligibility criteria were
adapted, allowing inclusion of this patient group with
thrombocytosis.
Trial Procedures
Patients randomly assigned to capecitabine were asked to
continue taking the drug until disease progression, death,
or intolerable toxicity. Capecitabine was dosed according to
standard guidelines, orally twice daily for 14 days followed
by a 7-day rest period without capecitabine tablets.
Patient tumor status was assessed every 8 weeks by CT
scan reviewed at the treating hospital site according to
RECIST version 1.1.9 Toxicities and symptoms were
assessed locally every 4 weeks from random assignment or
start of treatment using NCI CTCAE (version 3.0). Patients
were followed until progressive disease, at which point the
CONTEXT
Key Objective
In patients with metastatic colorectal cancer, first-line systemic anticancer therapy (SACT) with palliative intent aims to
extend overall survival (OS) while maintaining quality of life. Current guidelines recommend a maintenance strategy of
oral capecitabine and bevacizumab in patients with disease control after 4-6 months of induction SACT. This is based
upon improved progression-free survival (without evidence of OS benefit) compared with a complete treatment break
with active monitoring (AM). FOCUS4-N aims to establish the impact of maintenance capecitabine monotherapy versus
AM.
Knowledge Generated
These results demonstrate that capecitabine can double the time until return to induction SACT. However, patients may
adopt an AM approach without detriment in OS and with less toxicity.
Relevance
FOCUS4-N provides information for patients and clinicians, which will assist decision making at the end of induction SACT.
Capecitabine without intravenous bevacizumab is likely more cost-effective than the current recommended approach of
capecitabine and bevacizumab.
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patient was recommended to restart first-line systemic
therapy.
Treatment was stopped for grade $ 3 toxic effects or
persistent toxicities judged medically important or not tol-
erated by the patient, until the toxicity resolved to grade 1 or
better. After stopping treatment, capecitabine could be
reinitiated at a reduced dose. Any stoppage for $ 28 days
was not permitted, with the patient discontinued from trial
therapy but remaining under follow-up.
QoL data using EQ-5D were collected at random assign-
ment, every 8 (7-9) weeks until progression, 4 weeks after
end of trial treatment, 3 months after progression, and then
every 6 months.
Statistical Methods
Treatment allocation. Patients were allocated to capeci-
tabine or AM by a centrally managed telephone service at
the MRC Clinical Trials Unit at University College London,
using a 1:1 allocation ratio by minimization with a random
element of 20%. Minimization factors were treating hospital
site, primary tumor site (right colon, left colon, or rectum),
WHO performance status (0, 1, or 2), 16-week CT scan
result (stable disease and partial or complete response),
number of metastatic sites (none, one, or two or more), and
first-line therapy regimen (fluorouracil, capecitabine, or
neither; both oxaliplatin and irinotecan, irinotecan only, or
neither; and cetuximab or panitumumab, bevacizumab, or
no monoclonal antibody).
Outcome measures. The primary FOCUS4-N outcome was
PFS, defined as time from random assignment to either
disease progression (according to RECIST criteria) or death
from any cause. Patients without a PFS event were cen-
sored at the time of their last recorded CT scan. OS was a
secondary outcome, defined as time from random as-
signment to death from any cause with patients censored at
last recorded disease assessment, blood measurement, or
anticancer treatment. Other secondary outcomes included
safety, toxicity, QoL, and tumor response. QoL was ana-
lyzed using mixed-effects linear modeling with patient-level
random intercepts and time slopes, with differences by the
treatment arm tested by evaluating the area under the
curve from the model.
Sample size calculation. The FOCUS4-N target sample
size was calculated using the Analysis of Resources for
Trials program implemented in Stata software. Given that
the recruitment rate into FOCUS4-N was dependent on
the availability of other molecular comparisons, failure of
biomarker testing, or patient choice, exact recruitment
figures were unknown at the trial commencement. Various
scenarios were used to estimate the recruitment rate
over 5 years, and we assumed a 4-month median PFS
in the AM arm (on the basis of COIN trial data). A total of
644 patients (635 events) would provide 80% power
of detecting a hazard ratio (HR) of 0.8 at the two-sided
5% significance level.
In March 2020, the COVID-19 pandemic resulted in
temporary closure of FOCUS4 to new recruitment. Fol-
lowing Independent Data Monitoring Committee review
and recommendation, a decision was taken to close
recruitment permanently in April 2020 as trial funding
was nearing its end. A previous review of the implica-
tions of reduced recruitment on the statistical power of
FOCUS4-N had been considered by our funders who
recommended that, despite reduced power, the trial
should close in 2020 and report the data accrued up to
that point. Furthermore, at analysis, it became clear
that the observed HR was substantially more extreme
than the target HR on which we based our original
sample size.
Statistical analysis. All analyses were performed according
to a predefined statistical analysis plan agreed before
database lock. We analyzed using Stata statistical software,
version 16.1 (Stata Corporation, TX). The primary analysis
was performed according to intention-to-treat with a sec-
ondary per-protocol analysis defined by patients who
completed at least one cycle of trial treatment ($ 28 days).
Patients were censored according to the following criteria.
For survival status, we censored patients on the date that
they were last known to be alive, either via collection of
prescription from their hospital pharmacy or attendance at
a follow-up visit or CT scan. For PFS, we censored patients
without progression on the date of the last CT scan
showing no progression. For patients who died before any
follow-up visit or CT scan, we used the date of death as the
date of the event and assumed death without progression,
provided that the death occurred within 3 months of
random assignment or any previous scan confirming no
progression.
Kaplan-Meier curves were used to present survival data and
Cox regression modeling to estimate HRs between ran-
domized groups. Unadjusted HRs and the ones adjusted
for the stratification factors used to minimize patients into
allocated groups (primary analysis) were estimated. A
further analysis also adjusted for resection status, timing of
metastatic disease, alkaline phosphatase, white blood cell
count, age of tumor sample, and use of aspirin at baseline.
Deviation from nonproportional hazards was assessed




Across 88 UK hospitals, between January 2014 and March
2020, 1,434 patients were registered into FOCUS4, of
whom 924 underwent successful biomarker assessment
and completed 16 weeks of first-line therapy with either
stable or responding disease (Data Supplement). Of these
patients, 254 were randomly assigned to FOCUS4-N
(Fig 1), 127 to AM and 127 to maintenance capecitabine.
Journal of Clinical Oncology 3695
Capecitabine Maintenance in Metastatic Colorectal Cancer
Downloaded from ascopubs.org by University of Aberdeen on November 24, 2021 from 139.133.148.039
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Baseline demographic and clinical characteristics were
well-balanced between the study arms (Table 1 and Ap-
pendix Table A1, online only). Most patients had wide-
spread synchronous metastatic disease with about half
having an unresected primary tumor. A right-sided primary
tumor location was present in about one third. The majority
were treated with doublet chemotherapy (irinotecan-based
57%) without a monoclonal antibody (as bevacizumab
is not reimbursed in the United Kingdom). The Data
Supplement shows induction chemotherapy for all patients
Total registered





(n = 52) 
CR/PR/SD
(n = 868) 
Progressive disease      (n = 27)
Lost to follow-up             (n = 8) 
Not randomly assigned               (n = 39)
Of which
   Patient or clinician decision      (n = 26)
   Unable because of COVID-19     (n = 3)
   Toxicity                                        (n = 6)
   Others or unknown                     (n = 4)
Eligible for random assignment
(n = 924) 
Randomly assigned to FOCUS4-N
















Progressive disease      (n = 334)




  for molecular trials
    FOCUS4-B                 (n = 7)
    FOCUS4-C               (n = 13)
    FOCUS4-D               (n = 12)
Randomly assigned to B                (n = 6)
Randomly assigned to C              (n = 69)
Randomly assigned to D               (n = 32)
Not randomly assigned              (n = 524)
Of which
   Patient or clinician decision   (n = 308)
                                             
   Ineligible, eg, outside                (n = 96)
   timelines                               
   Unable because of COVID-19    (n = 27)
                                               
   Progressed or died                   (n = 26)
   Toxicity                                      (n = 48)
   Others or unknown                  (n = 19)
FIG 1. Flow diagram showing patient flow through the FOCUS4-N trial. CR, complete response; PR, partial response; SD, stable disease.
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in FOCUS4, and the Data Supplement shows disease re-
sponse to induction chemotherapy on the basis of bio-
marker subgroup. The molecular characteristics are shown
in Table 1 (and the Data Supplement for all FOCUS4
participants), showing that only 37% had an RAS wild-
type tumor reflecting NHS England policy of not allowing
treatment breaks for patients on epidermal growth factor
receptor monoclonal antibodies.
Compliance with randomized allocation was good with
only one patient in the AM arm receiving capecitabine
approximately 6 months before progression. Patients in







Mean (SD) age, years 63.7 (10.9) 64.7 (9.6)
Sex, No. (%)
Male 76 (60) 86 (68)
Female 51 (40) 41 (32)
Baseline WHO performance status,
No. (%)
0 76 (60) 80 (63)
1 49 (39) 45 (35)
2 2 (2) 2 (2)
Site of primary tumor, No. (%)
Right colon 45 (35) 47 (37)
Left colon 32 (25) 33 (26)
Rectum 50 (39) 47 (37)
Current state of primary tumor, No.
(%)
Resected primary 62 (49) 54 (43)
Unresected primary 61 (48) 68 (54)
Unresected local recurrence 4 (3) 5 (4)
No. of metastatic sites, No. (%)
No metastases 2 (2) 4 (3)
One 41 (32) 40 (31)
Two or more 84 (66) 83 (65)
Timing of metastases, No. (%)
Metachronous 40 (31) 21 (17)
Synchronous 85 (67) 101 (80)
No metastases 2 (2) 4 (3)
Missing data 0 (0) 1 (1)
Disease assessment at end of first-
line treatment, No. (%)
Complete response 3 (2) 5 (4)
Partial response 75 (59) 71 (56)
Stable disease 49 (39) 51 (40)
Fluoropyrimidine drug used during
first-line treatment, No. (%)
FU 95 (75) 97 (76)
Capecitabine 32 (25) 30 (24)
Oxaliplatin or irinotecan used during
first-line treatment, No. (%)
Both oxaliplatin and irinotecan 2 (2) 2 (2)
Oxaliplatin only 50 (39) 50 (39)
Irinotecan only 73 (57) 71 (56)
Neither 2 (2) 4 (3)
Monoclonal antibody used during
first-line treatment, No. (%)
(continued in next column)







Cetuximab/panitumumab 25 (20) 20 (16)
Bevacizumab 6 (5) 7 (6)
No antibody 96 (76) 100 (79)
PIK3CA mutation status, No. (%)
Mutation 15 (12) 14 (11)
Wild type 96 (76) 100 (79)
Failed 7 (6) 5 (4)
Insufficient tumor 9 (7) 8 (6)
BRAF mutation status, No. (%)
Mutation 13 (10) 17 (13)
Wild type 103 (81) 98 (77)
Failed 2 (2) 4 (3)
Insufficient tumor 9 (7) 8 (6)
RAS mutation status, No. (%)
Mutation 68 (54) 68 (54)
Wild type 47 (37) 48 (38)
Failed 3 (2) 3 (2)
Insufficient tumor 9 (7) 8 (6)
TP53 mutation status, No. (%)
Mutation 61 (48) 62 (49)
Wild type 33 (26) 28 (22)
Failed 3 (2) 2 (2)
Could not be tested 18 (14) 24 (19)
Insufficient tumor 12 (9) 11 (9)
MSI status, No. (%)
MSS 108 (85) 104 (82)
MSI 2 (2) 3 (2)
Failed 2 (2) 4 (3)
Could not be tested 6 (5) 8 (6)
Insufficient tumor 9 (7) 8 (6)
Total 127 (100) 127 (100)
Abbreviations: FU, fluorouracil; MSI, microsatellite instable; MSS,
microsatellite stable; SD, standard deviation.
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the capecitabine arm received a median of four cycles
(interquartile range, 2-8).
Primary Outcome: PFS
There were 122 of 127 PFS events in the AM arm and 117
of 127 in the capecitabine arm. The median PFS in the
capecitabine arm was 3.88 months (95% CI, 3.65 to 4.37)
and 1.87 months (95% CI, 1.81 to 2.14) in the AM arm.
Unadjusted and adjusted HRs were 0.44 (95% CI,
0.33 to 0.57), P, .0001 and 0.40 (95% CI, 0.21 to 0.75),
P , .0001, respectively. Figure 2 shows Kaplan-Meier
curves. Per-protocol analyses demonstrated very similar
findings; unadjusted and adjusted HRs were 0.42 (95%
CI, 0.32 to 0.55), P , .0001 and 0.38 (95% CI, 0.28 to
0.51), P , .0001, respectively. There was no evidence to
suggest deviation from the proportional hazards as-
sumption (P 5 .084).
OS
There were 90 of 127 deaths in the AM arm and 99 of
127 deaths in the capecitabine arm. The median time to
death was 15.2 months (95% CI, 12.1 to 18.5) in the AM
arm versus 14.8 months (95% CI, 23.7 to 18.6) in the
capecitabine arm, with no survival difference between
the arms; unadjusted and adjusted HRs were 1.00 (95%
CI, 0.75 to 1.33), P 5 .98 and 0.93 (95% CI, 0.69 to
1.27), P 5 .66, respectively. Kaplan-Meier curves are
presented in Figure 3. There was no evidence to suggest
deviation from the proportional hazards assumption
(P 5 .58).
Subgroup Analyses
Preplanned subgroup analysis for PFS (Fig 4A) suggested
better PFS with a maintenance strategy in left-sided tumors
(HR 0.38 v 0.56 for right-sided, interaction P5 .13), and a
similar observation was seen with OS (HR 0.82 for left-sided
v 1.37 for right-sided, interaction P 5 .076; Fig 4B). There
was a suggestion that patients with tumoral loss of phos-
phatase and tensin homolog and PIK3CA mutations may
show less benefit from maintenance capecitabine than
other molecular subgroups (PFS HR 0.74, OS HR 1.47),
although this was not statistically significant. For OS, the
only other notable subgroup effect was that those with
stable disease at random assignment appeared to benefit
frommaintenance capecitabine, whereas those with partial
response did not (OS HR 0.63 and 1.42, respectively,
interaction P 5 .005; Fig 4B). Swimmer plots show the
distribution of individual patient PFS duration and timing
of CT scans by left- versus right-sided disease (Appendix
Fig A1, online only).
Toxicity
Cumulative toxicities were substantially less in the AM arm,
with increased toxicities associated with capecitabine
maintenance including diarrhea, dry skin, fatigue, nausea,
and palmar-plantar erythema (PPE; Fig 5). Ideally, a
maintenance therapy should result in no toxicity. Incidence
of grade zero as the worst toxicity reported per patient is
therefore instructive and is as follows for AM and capeci-

















No. at risk (event):
AM 127 (5) 119 (63) 56 (11) 45 (27) 18 (1) 17 (9) 8 (2) 6 (3) 3 (0)
Capecitabine 127 (4) 120 (22) 97 (18) 78 (21) 56 (9) 47 (10) 37 (4) 33 (10) 23 (0)
FIG 2. Kaplan-Meier curve for PFS in FOCUS4-N. Cox regression HR, adjusted for minimization factors5 0.40
(95% CI, 0.21 to 0.75), P , .0001. Minimization factors: location of primary tumor (left, right, and rectum),
baseline WHO performance status, baseline disease assessment, No. of metastases, first-line therapy (flu-
oropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody), and biomarker cohort, stratified for FO-
CUS4 trial timepoints. AM, active monitoring; HR, hazard ratio; PFS, progression-free survival.
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67%, diarrhea 72% versus 46%, stomatitis 90% versus
77%, dry skin 83% versus 77%, PPE 87% versus 44%,
and anemia 69% versus 54% (Appendix Table A2, online
only).
During the trial, 51% of patients who received capecitabine
had at least one cycle delayed, 37% had a dose reduction,
and 34% missed at least one dose (within a cycle). Fifty
percent of capecitabine patients commenced at least four
cycles, and 25% commenced at least eight cycles.
QoL
EQ-5D forms were completed in 93% (AM) and 90%
(capecitabine) at baseline (prerandomization but post-
induction chemotherapy). The Protocol (online only)
mandated completion every 8 weeks until progression
and 6-monthly thereafter; for analysis purposes, all
available forms were forced into an 8-week schedule. On
this basis, 63%, 45%, and 33% of randomly assigned
patients had data available at 8, 16, and 24 weeks,
respectively, with continuous decline thereafter. Mod-
eling was applied to data up to 48 weeks, since data
became too sparse beyond this. No notable differences
were seen in mobility, self-care, usual activities, anxiety,
and depression. There was a suggestion that pain and
discomfort might have been experienced less within the
capecitabine maintenance arm (P5 .11, Fig 6). This may
be due to symptoms associated with increased rates of
progression in the AM arm.
DISCUSSION
Choices on how to proceed with palliative treatment, in the
large majority of patients with incurable mCRC, with stable
or responding disease after 16 weeks of first-line therapy
need careful consideration with the patient at the core.
Discussions must be informed by the impact of receiving
systemic anticancer therapy over the preceding period.
This should include evaluation of the burden of toxicity and
QoL, as well as the response to treatment. Pooled data from
key phase II and III trials suggest minimal impact on OS
from a maintenance or continuation strategy but do show
the ability to delay a return to full combination therapy by
implementation of a maintenance therapy. Notably, the
FOCUS4-N data support the use of an oral only therapy
(capecitabine) to extend PFS and delay a return to com-
bination therapy by an average of two months. There is a
clear cost to the patient for this improved PFS seen with
maintenance capecitabine including worse toxicity in terms
of diarrhea, fatigue, nausea, skin rash, and PPE albeit
mostly at grade # 2, and these factors should be used to
further inform decision making. There was no difference in
QoL scores between the two arms. It is notable that the
swimmer plots (Appendix Fig A1) suggest that about a third
of patients experience an extended PFS beyond 16 weeks
with maintenance capecitabine, suggesting significant
fluoropyrimidine sensitivity, while a third of patients dem-
onstrate relative insensitivity to fluoropyrimidine mono-
therapy and may indicate a further need to explore
AM
Capecitabine
No. at risk (event):
AM 127 (8) 110 (11) 91 (11) 75 (12) 58 (9) 47 (7) 38 (10) 27 (5) 20 (5) 15 (5) 9 (1) 8 (0)
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Analysis Time (months)
FIG 3. Kaplan-Meier curve for OS in FOCUS4-N. Cox regression HR, adjusted for minimization
factors 5 0.93 (95% CI, 0.69 to 1.27), P 5 .66. Minimization factors: location of primary tumor (left,
right, and rectum); baseline WHO performance status; baseline disease assessment; No. of metas-
tases; first-line therapy (fluoropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody); and
biomarker cohort, stratified for FOCUS4 trial timepoints. AM, active monitoring; HR, hazard ratio; OS,
overall survival.
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predictive biomarkers of efficacy for this strategy. Pre-
planned subgroup analysis suggests that patients with
stable disease at the end of 16-week induction period
may gain a significant survival benefit from maintenance
capecitabine, but this is not corroborated in other studies
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FIG 4. (A) Forest plot of subgroup analyses for PFS (unadjusted HRs). (B) Forest plot of subgroup analyses for OS (unadjusted HRs). AM, active
monitoring; CAPOX, capeciteabine with oxaliplatin; Cet, cetuximab; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX, infusional
fluorouracil, leucovorin, and oxaliplatin; HR, hazard ratio; OS, overall survival; Pan, panitumumab; PFS, progression-free survival; PTEN,
phosphatase and tensin homolog; PTL, primary tumor location. (continued on next page)
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Although this trial is underpowered to evaluate OS, it
demonstrates very similar median values of 14.8 versus
15.2 months between the two arms with an HR of 0.93
(P 5 .66) when adjusted for minimization factors. It is
informative to compare these data with those of CAIRO3,
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0.90 (0.64 to 1.29)
1.20 (0.73 to 1.98)
0.63 (0.40 to 0.99)
1.42 (0.97 to 2.10)
1.03 (0.65 to 1.63)
1.01 (0.70 to 1.47)
1.37 (0.83 to 2.24)
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bevacizumab maintenance with comparable effects on
PFS (HR 5 0.40, P , .0001; cfFOCUS4-N adjusted
HR 5 0.40, P , .0001) and nonsignificant OS effect
(HR 5 0.83, P 5 .06).4 Cross-trial comparisons carry
notable caveats and must be undertaken with caution as
CAIRO3 included patients with better prognosis than FO-
CUS4-N and both their median PFS and cycle number on
maintenance therapy were approximately double those of
ours. However, it does suggest that the main driver of PFS
improvement when using capecitabine plus bevacizumab
is the capecitabine. Individual patient data meta-analysis
has also shown no OS benefit from current maintenance
therapy strategies.8
On the basis of a subgroup analysis from the much larger
phase III COIN study,1 which demonstrated a survival
detriment in patients with a baseline thrombocytosis re-
ceiving a complete treatment break (HR 5 1.55;
P5 .0018), we elected not to recruit patients with baseline
thrombocytosis to the FOCUS4 trial program from January
2014 to June 2017. Wishing to validate or refute this
finding, we undertook an individual patient data meta-
analysis to assess thrombocytosis as a predictive marker
of the benefits or otherwise of an intermittent or contin-
uous therapy strategy.8 This evaluation did not validate our
COIN finding on thrombocytosis, and thus, trial eligibility
was adapted to allow these patients to enroll. Within
FOCUS4-N overall, 3% (n 5 8) of patients had baseline
thrombocytosis, and thus, our study is underpowered to
explore this predictive phenomenon further. Because of
our conservative approach, FOCUS4-N under-represents
approximately 25% of patients with mCRC who typically
have thrombocytosis at baseline, a known worse prog-
nosis group. However, given our findings in the individual
patient data meta-analysis, we do not feel that this
undermines our more general conclusions, which are
independent of baseline platelet count.
Owing to funding restrictions in the UK National Health
Service, bevacizumab is not routinely available for patients
with mCRC, and in patients with RAS wild-type tumors,
epidermal growth factor receptor monoclonal antibodies
are only available in the first-line setting, with restrictions in
England preventing treatment interruption of cetuximab/
panitumumab for longer than 6 weeks. Additionally, during
the FOCUS4-D trial recruitment period,10 patients with RAS
wild-type and BRAF wild-type tumors were eligible for
random assignment and were preferentially recruited into
that trial. These factors make for a selective group of pa-
tients recruited to FOCUS4-N during that time. From a
molecular perspective, 59% of patients randomly assigned
in the FOCUS4-N trial had an RAS mutation and 15% a
BRAFmutation. Reassuringly, the Forest plots (Figs 4A and
4B) do not show any significant differences in PFS or OS on
the basis of these molecular criteria.
In conclusion, despite strong evidence of disease control
with maintenance therapy, OS remains unaffected and
FOCUS4-N provides additional evidence to support the use
of treatment breaks as safe management alternatives for
patients entering treatment de-escalation after 16 weeks of
induction therapy for mCRC. If maintenance therapy is
selected following consideration of the advantages and
disadvantages in consultation with a particular patient,
capecitabine without bevacizumab may be used to extend
PFS, in the interval after doublet or triplet therapy, es-
sentially doubling the period before recommencing full-
dose induction therapy. Notably, these data also provide
tools to best inform the dialogue between patients and































































FIG 5. Cumulative reported toxicity by randomized group: (A) active monitoring (n5 127) and (B) capecitabine (n5 127). G, grade; PPE, palmar-
plantar erythema.
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FIG 6. Quality of life measured by EQ-5D by randomized group: (A) mobility: X2 for AUC difference 5 0.86(1),
P 5 .35; (B) self-care: X2 for AUC difference 5 1.64(1), P 5 .20; (C) usual activities: X2 for AUC
difference5 0.06(1), P5 .81; (D) pain and discomfort: X2 for AUC difference5 2.49(1), P5 .11; and (E) anxiety
and depression: X2 for AUC difference 5 1.03(1), P 5 .31; AUC, area under the curve.
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FIG A1. Swimmer plot for FOCUS4-N, by location of primary tumor. CT, computed
tomography.
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Median (IQR) Median (IQR)
WBC, 109/L 127 6.3 (2.2) 127 6.6 (8.8)
6.0 (4.6-7.4) 5.8 (4.9-7.6)
Neutrophils, 109/L 127 3.7 (1.8) 127 4.0 (3.4)
3.4 (2.4-4.7) 3.5 (2.5-4.8)
Platelets, 109/L 127 244 (90) 127 249 (83)
239 (190-284) 237 (184-294)
Serum bilirubin, mmol/L 127 8.7 (4.1) 127 8.3 (3.9)
8.0 (6.0-11.0) 8.0 (5.0-10.0)
ALP, U/L 127 132 (79) 127 112 (60)
110 (84-154) 98 (81-124)
AST/ALT, U/L 127 25.7 (14.5) 127 28.2 (17.5)
22 (16-31) 24 (17-34)
Renal function, mL/min 126 90.5 (28.6) 127 90.5 (27.3)
90 (69-100) 90 (71-101)
CEA, mg/L 122 96 (427) 125 83 (251)
6 (3-28) 8 (3-22)
LDH, U/L 115 369 (149) 114 429 (489)
353 (241-464) 376 (254-454)
Abbreviations: ALP, alkaline phosphatase; CEA, carcino embryonic antigen; IQR, interquartile range; LDH, lactate dehydrogenase; SD,
standard deviation.
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0 94 (74) 85 (67)
1 15 (12) 27 (21)
2 10 (8) 10 (8)
3 1 (1) 1 (1)
Missing 7 (6) 4 (3)
Vomiting
0 106 (83) 108 (85)
1 7 (6) 9 (7)
2 6 (5) 5 (4)
3 1 (1) 1 (1)
Missing 7 (6) 4 (3)
Diarrhea
0 92 (72) 58 (46)
1 19 (15) 40 (31)
2 6 (5) 19 (15)
3 3 (2) 6 (5)
Missing 7 (6) 4 (3)
Stomatitis
0 114 (90) 98 (77)
1 5 (4) 21 (17)
2 1 (1) 4 (3)
Missing 7 (6) 4 (3)
Dry skin
0 105 (83) 81 (64)
1 14 (11) 38 (30)
2 1 (1) 3 (2)
3 0 (0) 1 (1)
Missing 7 (6) 4 (3)
Skin rash
0 111 (87) 104 (82)
1 9 (7) 14 (11)
2 0 (0) 3 (2)
3 0 (0) 2 (2)
Missing 7 (6) 4 (3)
Nail dystrophy
0 110 (87) 105 (83)
1 9 (7) 16 (13)
2 1 (1) 2 (2)
Missing 7 (6) 4 (3)
(continued in next column)









0 111 (87) 56 (44)
1 5 (4) 35 (28)
2 4 (3) 25 (20)
3 0 (0) 7 (6)
Missing 7 (6) 4 (3)
Anemia
0 88 (69) 69 (54)
1 20 (16) 43 (34)
2 11 (9) 9 (7)
3 1 (1) 3 (2)
Missing 7 (6) 3 (2)
Neutropenia
0 114 (90) 115 (91)
1 3 (2) 4 (3)
2 0 (0) 2 (2)
3 0 (0) 2 (2)
4 2 (2) 1 (1)
Missing 8 (6) 3 (2)
Total 127 (100) 127 (100)
Abbreviation: PPE, palmar-plantar erythema.
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